Welcome to our dedicated page for Propanc Bio news (Ticker: PPCB), a resource for investors and traders seeking the latest updates and insights on Propanc Bio stock.
Propanc Biopharma, Inc. (PPCB) is a clinical-stage biopharmaceutical company pioneering enzyme-based therapies targeting aggressive cancers. This dedicated news hub provides investors and researchers with essential updates on preclinical developments, strategic partnerships, and regulatory milestones.
Access timely press releases covering PPCB's lead candidate PRP, designed for pancreatic and ovarian cancers, along with progress reports from collaborative research initiatives. Our curated feed includes financial filings, intellectual property updates, and scientific presentations - all critical for tracking this innovative oncology developer.
Bookmark this page to monitor PPCB's progress in advancing synergistic enzyme formulations through preclinical studies. Stay informed about emerging research from their POP1 joint program and other academic collaborations shaping next-generation cancer therapies.
Propanc Biopharma, Inc. (OTCQB: PPCB) announced a Notice of Allowance from the European Patent Office for its second patent application regarding compositions of proenzymes to treat cancer, expiring in November 2036. This patent will support higher dosing in upcoming clinical studies for its lead product candidate, PRP. A third application is under examination for treating cancer stem cells. The company’s IP portfolio now includes 65 patents, with plans for further patent applications based on recent discoveries.
Propanc Biopharma (OTC-PINK:PPCB) has entered a Joint Research Collaboration Agreement with the Universities of Jaén and Granada, Spain, focused on the effects of proenzyme therapy on the tumor microenvironment, vital for cancer progression. Research led by Mrs. Belén Toledo Cutillas shows proenzymes can reverse malignant phenotypes, presenting potential for differentiation therapy. The company retains all intellectual property rights from this project, which may expand its patent portfolio related to its lead product candidate, PRP, an intravenous treatment composed of proenzymes.
Propanc Biopharma, Inc. (OTC-PINK:PPCB) highlights significant research advancements in proenzyme therapy (PRP) for treating metastatic cancer from solid tumors. Chief Scientific Officer, Dr. Julian Kenyon, emphasizes PRP's unique capability to induce cancer cell differentiation, hindering their malignancy. Five scientific publications since 2013 showcase PRP's effectiveness against various solid tumors, demonstrating its potential to extend patient survival without severe side effects typical of standard treatments. Ongoing research focuses on PRP's impact on the tumor microenvironment, with promising preliminary results.
Propanc Biopharma, Inc. (OTCQB: PPCB) has announced the successful production of a synthetic recombinant form of the proenzyme trypsinogen through its Proenzyme Optimization Project (POP1). This initiative aims to create a backup clinical candidate for its lead product, PRP, targeting the expected
Propanc Biopharma, Inc. (OTCQB: PPCB) announced progress in developing its cancer treatment, PRP, which is set to enter Phase I clinical trials for advanced cancer patients. CEO James Nathanielsz emphasized PRP's potential as a less toxic alternative to standard therapies, with a third-party valuation of its intellectual property assets at $26 million. The company has received Orphan Drug Designation from the FDA for treating pancreatic cancer, providing various financial incentives. Propanc also secured a Certificate for Advance Overseas Finding from the Australian government, promising up to 43.5% cash back on overseas R&D expenses.
Propanc Biopharma, Inc. (OTCQB: PPCB) announced a robust intellectual property portfolio with 39 granted patents and 26 pending applications for its lead product candidate, PRP, aimed at treating solid tumors. The unique formulation targets and eradicates cancer stem cells using proenzymes trypsinogen and chymotrypsinogen. Future applications are expected to enhance treatment options for advanced cancer patients. The company is advancing a synthetic version of PRP and is optimistic about its market position against competitors in the proenzyme space.
Propanc Biopharma, Inc. filed a Definitive Information Statement under Section 14C of the Exchange Act on June 9, 2022, to increase authorized shares and allow for a potential reverse stock split at the board's discretion. CEO James Nathanielsz noted that this move is essential due to recent volatile market conditions impacting microcap companies. The company is committed to advancing its lead product candidate, PRP, which is designed to target various cancers, and is actively pursuing strategic partnerships for clinical development.
Propanc Biopharma, Inc. (OTCQB: PPCB) announced encouraging results from a small trial involving 18 rectal cancer patients in complete remission using the immunotherapy dostarlimab. The Chief Scientific Officer, Dr. Julian Kenyon, noted the challenges in immunotherapies' inconsistent effectiveness across cancer types. PRP, the company’s lead product, targets cancer stem cells and aims to improve treatment efficacy. While the trial showed promise, metastatic cancer remains a major hurdle in treatment. PRP is a mixture of proenzymes aimed at preventing cancer recurrence and metastasis.
Propanc Biopharma (PPCB) announces its lead product, PRP, aims to treat solid tumors by targeting and eradicating cancer stem cells (CSCs), responsible for tumor recurrence and metastasis. With solid tumors accounting for 80-90% of cancer cases, PRP could significantly impact treatment strategies. The therapy consists of proenzymes trypsinogen and chymotrypsinogen, which inhibit tumor growth. Research indicates PRP may be effective against aggressive tumors, including sarcomas—an underserved patient population—potentially revolutionizing cancer treatment.
Propanc Biopharma (OTC-PINK:PPCB) announces advancements in its cancer treatment, PRP, which aims to reduce toxicity compared to standard therapies for metastatic cancer. Chief Scientific Officer Dr. Julian Kenyon highlights the urgent need for safer, more effective treatments, as metastatic cancer accounts for 90% of cancer deaths in the U.S. Clinical trials show minimal side effects, improving patient quality of life. The company plans a First-In-Human study, aiming to extend life and reduce cancer-related suffering.
